Professor Zhang Rongxuan (left) and Dr. Zhu Hui (right) sign a strategic agreement

Vice President of Jufeel Fu Wenxing, Dr. Zhu Hui, Professor Zhang Rongxuan,

　　Chinanews.com Henan branch reported on May 12. On May 12, 2018, the NEWGEN company actual controller, Chairman of Ningbo NEWGEN Marine Biotechnology Co., Ltd. and Haimen Xinuo Biomedical Company Zhu Hui and Jufeel Group chairman Zhang Rongxuan sign Strategic Merger Agreement in the NEWGEN Science Park in Xiangshan, Ningbo, Zhejiang Province, and acquire the three assets of NEWGEN Company, Ningbo NEWGEN Marine Life Company and Haimen NEWGEN Biomedical Company, to jointly achieve the strategy of "global aloe biological expert" and "global enzyme preparation biomedical expert" being listed in United States .

　　The signing of this strategic Merge and Acquisition Agreement marks that the two brands with a profound influence in the bio-area of "Aloe PMAS" and the "Enzyme Preparation" bio-area will start to create a bright future. This company merger will surely have a profound influence in the global bio-industry. In the future, the two companies will rely on their respective resource advantages to strengthen global cooperation in various fields such as industry, capital and technology, and help the two sides to accelerate company's development.

　　It is reported that the actual controller of the three companies, NEWGEN Company, Ningbo NEWGEN Marine Life Company and Haimen NEWGEN Biomedical Company is Dr. Zhu Hui, who is a member of The Recruitment Program of Global Experts in Zhejiang Province.

　　Zhu Hui, a Ph.D. student in biochemistry at the University of Hong Kong, spends 15 years in medical research in the United States. He is a postdoctoral fellow in immunology at the University of Maryland and a postdoctoral fellow in immunology at the University of Southern California Los Angeles Children's Hospital. He was a R&D director of SEB enzyme bioengineering company in the United States. In 2012, he founded the Huitai Bioengineering Company of California specializing in biotechnology research and development. His research and development achievements have won the first prize of "Zhejiang Thousand People Plan", Ningbo City 3315 plan, the China Science and Technology Entrepreneurship Competition sponsored by the Ministry of Science and Technology.

　　In January 2013, in order to break the long-term technological monopoly of developed countries, Dr. Zhu Hui (the actual controller and chief scientist of NEWGEN Company of the United States and the expert of “Thousand Talents Program” of Zhejiang Province) officially leads the team to return to China and starts business. He establishes Ningbo NEWGEN Marine Biotechnology in Zhejiang in November and begins production and development of enzyme preparations and derivatives. After nearly five years of development, NEWGEN has a research and development center for modern enzyme fermentation and enzymatic hydrolysis technology and an annual production capacity of 40 tons of enzyme preparation and marine yeast fermentation plant; he establishes a complete strain library with more than 3,000 species, more than 60 patented technologies; it is one of the most abundant strain library of marine microbial strains at home and abroad.

　　According to Dr. Zhu Hui, enzymes are a class of special proteins with high catalytic activity synthesized by cell protoplasts, also known as “biocatalysts”. They are widely used in industry, medicine, agriculture, chemical analysis, environmental protection, energy development and life science fields. At present, more than 80% of the enzyme preparation market in China is occupied by the United States company' products. During his early years at the University of Maryland, he studied under the prestigious Nobel Prize winner in Physiology and Medicine, Professor David Baltimore, the originator of immunology. At present, the US NEWGEN company controlled by him has a number of Nobel Prize winners in physiology and medicine as the leader of the research and development team. It has a US R&D team composed of dozens of American scientists and a global advanced high-throughput semiconductor chip screening Super class laboratory.